CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings data on Wednesday. The medical technology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.01, Market Beat.com reports.

Several research firms have weighed in on CNMD. Zacks Investment Research upgraded CONMED from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research report on Thursday, January 14th. Leerink Swann reiterated a “buy” rating on shares of CONMED in a research report on Monday, November 16th. Needham & Company LLC reiterated a “buy” rating on shares of CONMED in a research report on Monday, November 16th. Deutsche Bank restated a “buy” rating on shares of CONMED in a research report on Tuesday, November 17th. Finally, Ladenburg Thalmann upgraded CONMED from a “neutral” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Monday, October 12th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $54.33.

In other CONMED news, Director David M. Bronson acquired 1,500 shares of the business’s stock in a transaction on Friday, December 11th. The shares were acquired at an average price of $41.01 per share, with a total value of $61,515.00. Following the completion of the transaction, the director now owns 1,500 shares in the company, valued at $61,515. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

An institutional investor recently raised its position in CONMED stock. Russell Frank Co boosted its position in shares of CONMED Co. (NASDAQ:CNMD) by 4.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The hedge fund owned 163,834 shares of the medical technology company’s stock after buying an additional 6,360 shares during the period. Russell Frank Co owned approximately 0.59% of CONMED worth $7,268,000 at the end of the most recent quarter.

CONMED (NASDAQ:CNMD) traded down 1.30% on Wednesday, reaching $38.58. The company’s stock had a trading volume of 198,238 shares. The stock’s 50 day moving average price is $41.38 and its 200 day moving average price is $47.60. The firm has a market cap of $1.07 billion and a PE ratio of 31.62. CONMED has a 52-week low of $36.76 and a 52-week high of $60.66.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 5th. Shareholders of record on Tuesday, December 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date of this dividend was Friday, December 11th.

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Its product lines consist of orthopedic surgery, general surgery and surgical visualization. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments. General surgery consists of a line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. Surgical visualization consists of 2D and 3D video systems for use in minimally invasive orthopedic and general surgery.

12 Month Chart for NASDAQ:CNMD

Receive News & Ratings for CONMED Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Co. and related companies with MarketBeat.com's FREE daily email newsletter.